Recent developments include the announcement of groundbreaking top-line results from the PRIME Phase 1b clinical study and a special webcast to review positive clinical data in September 2025. Earlier news covers corporate milestones such as business combination approvals and scientific advisory board appointments.

• Revelation Biosciences announced groundbreaking top-line results from the PRIME Phase 1b clinical study in September 2025 [N2].
• The company held a special webcast to review positive top-line clinical data in September 2025 [N1].
• A reminder webcast/conference call was scheduled to discuss the PRIME Phase 1b top-line data in September 2025 [N3].
• Petra Acquisition, Inc. announced share redemption backstop and forward purchase agreements related to Revelation Biosciences business combination in December 2021 [N4].
• Petra Acquisition, Inc. announced a special meeting of stockholders to approve the business combination with Revelation Biosciences in December 2021 [N5].
• Revelation Biosciences appointed Joseph A. Bellanti, M.D. to its Scientific Advisory Board in December 2021 [N6].
• The company announced the creation and appointments to its Scientific Advisory Board in November 2021 [N8].

The company's proprietary Gemini platform addresses critical unmet needs in kidney diseases by modulating inflammation, a key driver of AKI and CKD progression. Positive preclinical and clinical data support Gemini's potential efficacy. FDA agreement on a Phase 2/3 adaptive trial design for AKI and ongoing preparations for clinical studies demonstrate progress in development. The platform's broader immunomodulatory properties may enable expansion into other indications through collaborations or out-licensing, potentially unlocking additional value [S1][N2].

Revelation Biosciences faces significant risks including the absence of approved products and reliance on external financing to fund operations, which may not be available on acceptable terms. The company is subject to Nasdaq listing risks under new rules that could lead to delisting and reduced liquidity. Clinical development carries inherent uncertainties, and failure to achieve regulatory approval or commercial viability could adversely affect the company. The Rights Agreement adopted may deter potential favorable takeover offers, potentially impacting shareholder value [S2].

Revelation Biosciences' moat lies in its proprietary Gemini platform, which leverages a synthetic TLR4 agonist to modulate immune response and inflammation, a novel approach targeting significant unmet medical needs in kidney diseases. The platform's potential to treat both acute and chronic kidney conditions through immunomodulation, supported by preclinical and clinical data, positions the company uniquely in a market with no approved therapies for AKI and limited options for CKD. The company's strategic focus on kidney-related diseases and plans for clinical development and regulatory approval further contribute to its competitive positioning [S1].

• Nasdaq Listing Risk: The company faces potential delisting from Nasdaq under the new MVLS Rule if its market value remains below $5 million for 30 consecutive business days, which could reduce liquidity and market visibility [S2].
• Financing Risk: Revelation requires substantial additional capital to continue operations and fund clinical development. Failure to secure financing on acceptable terms could delay or curtail development programs [S2].
• Clinical and Regulatory Risk: The success of Gemini depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain and may impact the company's ability to commercialize its products [S1].
• Anti-Takeover Measures: The Rights Agreement adopted in 2026 may discourage takeover attempts, potentially limiting shareholder opportunities for premium transactions [S2].

• Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health using its proprietary Gemini formulation platform based on PHAD®, a synthetic Toll-like receptor 4 (TLR4) agonist [S1].
• The company’s lead product candidate, Gemini, is being developed primarily for kidney-related diseases including acute kidney injury (AKI) and chronic kidney disease (CKD) [S1].
• Gemini modulates the immune response by controlled stimulation of TLR4, aiming to restore inflammatory equilibrium and foster healing [S1].
• AKI is characterized by rapid loss of kidney function with no approved therapies other than supportive care and dialysis; Gemini is being evaluated as a potential treatment to attenuate hyperinflammation in AKI [S1].
• CKD is a progressive kidney function decline often caused by diabetes, hypertension, or prior AKI; Gemini is being evaluated for its potential to reduce inflammation and prevent scarring in CKD [S1].
• The company has conducted preclinical studies demonstrating Gemini’s ability to reduce fibrosis and inflammation in kidney disease models [S1].
• Revelation has engaged with the FDA and obtained agreement on a single Phase 2/3 adaptive design study for AKI with a primary composite endpoint of death and/or dialysis, aiming for NDA submission [S1].
• Plans for 2026 include building infrastructure for the Phase 2/3 AKI study, including scientific advisory board engagement, clinical research organization partnerships, and drug manufacturing [S1].
• The company intends to conduct preclinical toxicology studies in 2026 to support a repeat dose Phase 2 study for CKD [S1].
• Revelation Biosciences was incorporated in Delaware in 2019 and is based in San Diego, California [S1].
• The company’s common stock and warrants trade on Nasdaq under symbols REVB and REVBW [S1].
• Recent corporate actions include multiple reverse stock splits between 2024 and 2026 to consolidate shares [S1].
• Financial snapshot as of September 30, 2026, shows cash and equivalents of approximately $9.12 million, current assets of about $9.27 million, current liabilities of $2.33 million, resulting in a current ratio of 3.98 and cash ratio of 3.93 [S2].
• Net loss for the nine months ended September 30, 2026, was approximately $3.32 million with basic and diluted EPS of -$5.92 [S2].
• The company has no approved products and does not generate revenue from product sales; it depends on external financing to fund operations [S2].
• Risk factors include potential Nasdaq delisting due to low market capitalization under new MVLS Rule, need for substantial additional financing, and anti-takeover rights plan adopted in 2026 [S2].
• Recent news highlights include announcement of groundbreaking top-line results from the PRIME Phase 1b clinical study and a special webcast to review positive clinical data in September 2025 [N1][N2][N3].
• Earlier news from 2021 documents business combination with Petra Acquisition, Inc., appointments to scientific advisory board, and initiation of clinical studies for REVTx-99, a treatment candidate for respiratory viral infections [N4][N5][N6][N7][N8].